Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
HIMS · NYSE · Healthcare
Fundamental quality
69
out of 100
Hims & Hers Health, Inc. is in full growth mode but not yet profitable: revenue is growing strongly (69.5% a year), but it doesn't translate into earnings yet. On fundamental quality it scores 69 out of 100, profiling it as a company of reasonable quality. Its weakest area is its profitability (net margin -0.6%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Hims & Hers is a consumer telehealth platform: online consultations and home-delivered medications by subscription, in areas like sexual health, hair loss, mental health and weight loss. Its strength is brand and direct-to-consumer marketing.
Revenue growth: 69.5%
Net margin: -0.6% · ROE: -3%
Net debt/EBITDA: -5.92x · FCF: 2.5%
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its profitability drags it down the most.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 149 | -18 | — | -27 |
| 2021 | 272 | -108 | — | -72 |
| 2022 | 527 | -66 | -34 | -47 |
| 2023 | 872 | -24 | 47 | -97 |
| 2024 | 1,477 | 126 | 198 | -221 |
| 2025 | 2,348 | 128 | 57 | -229 |
Between 2020 and 2025, revenue went from $149M to $2,348M (+1478%) and net income went from -$18M to $128M (+809%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Is Hims & Hers Health, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Hims & Hers Health, Inc. a good company to invest in?
In terms of business quality, Hims & Hers Health, Inc. scores 69 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Hims & Hers Health, Inc. a profitable company?
Over the last twelve months, no: Hims & Hers Health, Inc. posts a negative net margin (-0.6%).
Does Hims & Hers Health, Inc. have a lot of debt?
No. Hims & Hers Health, Inc. has a net cash position: more cash than debt.
Is Hims & Hers Health, Inc. growing?
Its revenue has grown 69.5% annualized in recent years, and without interruption since 2020.
Does Hims & Hers Health, Inc. generate cash?
Yes. It converts about 2.5% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
AbbVie (ABBV) · Merck (MRK) · Thermo Fisher Scientific (TMO) · Abbott Laboratories (ABT) · Intuitive Surgical (ISRG) · Pfizer (PFE) · see more →